Detailed Information on Publication Record
2011
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
JUŘICA, Jan, Richard BARTEČEK, Ondřej ZENDULKA, Tomáš KAŠPÁREK, Eva PINDUROVÁ et. al.Basic information
Original name
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Name in Czech
Stanovení fenoptypu a genotypu CYP2D6 s ohledem na predikci terapeutické odpovědi u prvních epizod schizofrenie
Name (in English)
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Authors
JUŘICA, Jan (203 Czech Republic, guarantor, belonging to the institution), Richard BARTEČEK (203 Czech Republic, belonging to the institution), Ondřej ZENDULKA (203 Czech Republic, belonging to the institution), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution), Eva PINDUROVÁ (203 Czech Republic) and Alexandra ŠULCOVÁ (203 Czech Republic, belonging to the institution)
Edition
The 61th Czech-Slovak Pharmacological days and EPHAR symposium, 2011
Other information
Language
Czech
Type of outcome
Konferenční abstrakt
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/11:00056990
Organization unit
Faculty of Medicine
ISBN
978-80-7399-770-0
Keywords (in Czech)
CYP2D6; genotyp; fenotyp; schizofrenie
Keywords in English
CYP2D6; genotype; phenotype; schizophrenia
Změněno: 28/11/2011 09:07, Mgr. Michal Petr
V originále
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
In English
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Links
| NS9676, research and development project |
|